Completed PHASE4 INTERVENTIONAL 2-arm NCT00625560

Continuing Lamivudine vs Switching to Entecavir in Patients With Detectable HBV DNA

Randomized, Open-Labelled Study Evaluating the Antiviral Efficacy, Safety, and Tolerability of Continuing Lamivudine Therapy or Switching to Entecavir in Subjects With Chronic Hepatitis B With Detectable HBV DNA

Sponsor: Pusan National University Hospital

Conditions Hepatitis B, Chronic

Interventions Entecavir Lamivudine

Updated 6 times since 2017 Last updated: May 7, 2012 Started: Feb 29, 2008 Primary completion: Nov 30, 2009 Completion: Nov 30, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Hepatitis B, Chronic and is currently completed. Pusan National University Hospital leads this study, which shows 6 recorded versions since 2008 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Feb 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pusan National University Hospital
Yonsei University

Data source: Yonsei University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Busan, South Korea
• Seoul, South Korea